A new coronavirus associated with human respiratory disease in China.
Nature. 2020; 579: 265-269
Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China.
Lancet. 2020; 395: 497-506
Pathophysiology of acute respiratory syndrome coronavirus 2 infection: a systematic literature review to inform EULAR points to consider.
RMD Open. 2021; 7e001549
COVID-19: risk for cytokine targeting in chronic inflammatory diseases?.
Nat Rev Immunol. 2020; 20: 271-272
Vaccinations in adults with rheumatoid arthritis in an era of new disease-modifying anti-rheumatic drugs.
Clin Exp Rheumatol. 2018; 36: 317-328
Risk of serious infection in biological treatment of patients with rheumatoid arthritis: a systematic review and meta-analysis.
Lancet. 2015; 386: 258-265
Opportunistic infections and biologic therapies in immune-mediated inflammatory diseases: consensus recommendations for infection reporting during clinical trials and postmarketing surveillance.
Ann Rheum Dis. 2015; 74: 2107-2116
Rheumatoid arthritis and the incidence of influenza and influenza-related complications: a retrospective cohort study.
BMC Musculoskelet Disord. 2012; 13: 158
Incidence and prevalence of vaccine preventable infections in adult patients with autoimmune inflammatory rheumatic diseases (AIIRD): a systemic literature review informing the 2019 update of the EULAR recommendations for vaccination in adult patients with AIIRD.
RMD Open. 2019; 5e001041
Serious infection risk in rheumatoid arthritis compared with non-inflammatory rheumatic and musculoskeletal diseases: a US national cohort study.
RMD Open. 2019; 5e000935
The risk of infections associated with rheumatoid arthritis, with its comorbidity and treatment.
Rheumatology (Oxford). 2013; 52: 53-61
The risk of infections with biologic therapies for rheumatoid arthritis.
Semin Arthritis Rheum. 2010; 39: 327-346
Risk of serious infection among patients receiving biologics for chronic inflammatory diseases: usefulness of administrative data.
J Adv Res. 2018; 15: 87-93
Risk of infectious complications in patients taking glucocorticosteroids.
Rev Infect Dis. 1989; 11: 954-963
Infections associated with steroid use.
Infect Dis Clin North Am. 2001; 15 (): 423-432
Infection risk in rheumatoid arthritis and spondyloarthropathy patients under treatment with DMARDs, corticosteroids and TNF-α antagonists.
J Transl Med. 2014; 12: 77
Clinical trial and registry data.
Curr Probl Dermatol. 2018; 53: 15-27
Global rheumatology in the time of COVID-19.
Lancet Rheumatol. 2020; 2: e254-e255
Factors associated with COVID-19-related death using OpenSAFELY.
Nature. 2020; 584: 430-436
Collider bias undermines our understanding of COVID-19 disease risk and severity.
Nat Commun. 2020; 115749
Impact of corticosteroids and immunosuppressive therapies on symptomatic SARS-CoV-2 infection in a large cohort of patients with chronic inflammatory arthritis.
Arthritis Res Ther. 2020; 22: 290
COVID-19 in French patients with chronic inflammatory rheumatic diseases: clinical features, risk factors and treatment adherence.
Joint Bone Spine. 2021; 88105095
Incidence of COVID-19 in patients with rheumatic diseases treated with targeted immunosuppressive drugs: what can we learn from observational data?.
Arthritis Rheumatol. 2020; 72: 1600-1606
Hospital admissions in inflammatory rheumatic diseases during the peak of COVID-19 pandemic: incidence and role of disease-modifying agents.
Ther Adv Musculoskelet Dis. 2021; 13 ()
Gout, rheumatoid arthritis, and the risk of death related to coronavirus disease 2019: an analysis of the UK biobank.
ACR Open Rheumatol. 2021; 3: 333-340
COVID-19 in patients with inflammatory arthritis: a prospective study on the effects of comorbidities and disease-modifying antirheumatic drugs on clinical outcomes.
Arthritis Rheumatol. 2020; 72: 1981-1989
COVID-19 and rheumatic autoimmune systemic diseases: report of a large Italian patients series.
Clin Rheumatol. 2020; 39: 3195-3204
Biologics increase the risk of SARS-CoV-2 infection and hospitalization, but not ICU admission and death: real-life data from a large cohort during red-zone declaration.
Dermatol Ther. 2020; 33e13475
Lack of evidence for an increased risk of severe COVID-19 in psoriasis patients on biologics: a cohort study from northeast Italy.
Am J Clin Dermatol. 2020; 21: 749-751
The impact of the COVID-19 pandemic on patients with chronic plaque psoriasis being treated with biological therapy: the northern Italy experience.
Br J Dermatol. 2020; 183: 373-374
Risk of hospitalization and death from COVID-19 infection in patients with chronic plaque psoriasis receiving a biologic treatment and renal transplant recipients in maintenance immunosuppressive treatment.
J Am Acad Dermatol. 2020; 83: 285-287
Severe COVID-19 outcomes in patients with psoriasis.
J Eur Acad Dermatol Venereol. 2020; 34: e776-e778
Uneventful course in patients with inflammatory bowel disease during the severe acute respiratory syndrome coronavirus 2 outbreak in northern Italy.
Gastroenterology. 2020; 159: 371-372
Outcomes of COVID-19 in 79 patients with IBD in Italy: an IG-IBD study.
Gut. 2020; 69: 1213-1217
Baseline disease activity and steroid therapy stratify risk of COVID-19 in patients with inflammatory bowel disease.
Gastroenterology. 2020; 159 (): 1541
Incidence of COVID-19 in an Italian cohort of patients with systemic lupus erythematosus: an observational survey.
Clin Exp Rheumatol. 2021; 39: 13
Incidence and clinical course of COVID-19 in patients with connective tissue diseases: a descriptive observational analysis.
J Rheumatol. 2020; 471296
COVID19 infection in a northern Italian cohort of systemic lupus erythematosus assessed by telemedicine.
Ann Rheum Dis. 2020; 79: 791382-791383
The table 2 fallacy: presenting and interpreting confounder and modifier coefficients.
Am J Epidemiol. 2013; 177: 292-298
Risk of COVID-19 in rheumatoid arthritis: a national veterans affairs matched cohort study in at-risk individuals.
Arthritis Rheumatol. 2021; ()
Psoriasis in the US medicare population: prevalence, treatment, and factors associated with biologic use.
J Invest Dermatol. 2015; 135: 2955-2963
Biologic agents in psoriasis: our experience during coronavirus infection.
Int J Dermatol. 2020; 59: e266-e267
Psoriasis: classical and emerging comorbidities.
Ann Bras Dermatol. 2015; 90: 09-20
The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017.
Lancet Gastroenterol Hepatol. 2020; 5: 17-30
Elevated markers of gut leakage and inflammasome activation in COVID-19 patients with cardiac involvement.
J Intern Med. 2021; 289: 523-531
Expression of SARS-CoV-2 entry molecules ACE2 and TMPRSS2 in the gut of patients with IBD.
Inflamm Bowel Dis. 2020; 26: 797-808
Implications of COVID-19 for patients with pre-existing digestive diseases.
Lancet Gastroenterol Hepatol. 2020; 5: 425-427
Seroprevalence of SARS-CoV2 in IBD patients treated with biological therapy.
J Crohn’s Colitis. 2021; 15: 864-868
Effect of IBD medications on COVID-19 outcomes: results from an international registry.
Gut. 2021; 70: 725-732
SARS-CoV-2 testing, prevalence, and predictors of COVID-19 in patients with inflammatory bowel disease in northern California.
Gastroenterology. 2020; 159 (): 1141
Infections and IBD.
Nat Clin Pract Gastroenterol Hepatol. 2008; 5: 18-27
Infection-related morbidity and mortality in patients with connective tissue diseases: a systematic review.
Clin Rheumatol. 2007; 26: 663-670
Prevalence and clinical outcomes of COVID-19 in patients with autoimmune diseases: a systematic review and meta-analysis.
Ann Rheum Dis. 2021; 80: 384-391
Clinical outcomes of hospitalised patients with COVID-19 and chronic inflammatory and autoimmune rheumatic diseases: a multicentric matched cohort study.
Ann Rheum Dis. 2020; 79: 1544-1549
Dexamethasone in hospitalized patients with COVID-19.
N Engl J Med. 2021; 384: 693-704
Effect of systemic glucocorticoids on mortality or mechanical ventilation in patients with COVID-19.
J Hosp Med. 2020; 15: 489-493
Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry.
Ann Rheum Dis. 2020; 79: 859-866
Corticosteroids, but not TNF antagonists, are associated with adverse COVID-19 outcomes in patients with inflammatory bowel diseases: results from an international registry.
Gastroenterology. 2020; 159: 481-491
Coronavirus disease 2019, immune-mediated inflammatory diseases and immunosuppressive therapies—a Danish population-based cohort study.
J Autoimmun. 2021; 118102613
Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry.
Ann Rheum Dis. 2021; 80: 930-942
Response to: Correspondence on factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician reported registry by Mulhearn et al.
Ann Rheum Dis. 2021; ()
Patients with immune-mediated inflammatory diseases receiving cytokine inhibitors have low prevalence of SARS-CoV-2 seroconversion.
Nat Commun. 2020; 113774
Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: Results from the COVID-19 Global Rheumatology Alliance physician registry.
Ann Rheum Dis. 2021; ()
Incidence of severe COVID-19 in a Spanish cohort of 1037 patients with rheumatic diseases treated with biologics and JAK-inhibitors.
Ann Rheum Dis. 2020; ()
Coronaviruses and immunosuppressed patients: the facts during the third epidemic.
Liver Transpl. 2020; 26: 832-834
COVID-19: consider cytokine storm syndromes and immunosuppression.
Lancet. 2020; 395: 1033-1034
Effect of tocilizumab vs standard care on clinical worsening in patients hospitalized with COVID-19 pneumonia: a randomized clinical trial.
JAMA Intern Med. 2021; 181: 24-31
Effect of tocilizumab vs usual care in adults hospitalized with COVID-19 and moderate or severe pneumonia: a randomized clinical trial.
JAMA Intern Med. 2021; 181: 32-40
Efficacy of tocilizumab in patients hospitalized with COVID-19.
N Engl J Med. 2020; 383: 2333-2344
Baricitinib therapy in COVID-19: A pilot study on safety and clinical impact.
J Infect. 2020; 81: 318-356
Baricitinib improves respiratory function in patients treated with corticosteroids for SARS-CoV-2 pneumonia: an observational cohort study.
Rheumatology (Oxford). 2021; 60: 399-407
Tofacitinib in patients hospitalized with COVID-19 pneumonia.
N Engl J Med. 2021; ()
SARS-CoV-2 outbreak in immune-mediated inflammatory diseases: the Euro-COVIMID multicentre cross-sectional study.
Lancet Rheumatol. 2021; 3: e481-e488
Tofacitinib’s infectious profile: concerns for clinical practice.
Lancet Rheumatol. 2020; 2: e65-e67
The risk of infection and malignancy with tumor necrosis factor antagonists in adults with psoriatic disease: a systematic review and meta-analysis of randomized controlled trials.
J Am Acad Dermatol. 2011; 64: 1035-1050
Factors associated with adverse COVID-19 outcomes in patients with psoriasis-insights from a global registry-based study.
J Allergy Clin Immunol. 2021; 147: 60-71
Persisting SARS-CoV-2 viraemia after rituximab therapy: two cases with fatal outcome and a review of the literature.
Br J Haematol. 2020; 190: 185-188
High rates of severe disease and death due to SARS-CoV-2 infection in rheumatic disease patients treated with rituximab: a descriptive study.
Rheumatol Int. 2020; 40: 2015-2021
Mild COVID-19 in ANCA-associated vasculitis treated with rituximab.
Ann Rheum Dis. 2020; 80: e99
Rituximab for granulomatosis with polyangiitis in the pandemic of covid-19: lessons from a case with severe pneumonia.
Ann Rheum Dis. 2021; 80: e10
Increased risk for severe COVID-19 in patients with inflammatory rheumatic diseases treated with rituximab.
Ann Rheum Dis. 2020; 80: e67
COVID-19 outcomes in patients with inflammatory rheumatic and musculoskeletal diseases treated with rituximab: a cohort study.
Lancet Rheumatol. 2021; 3: e419-e426
Safety and immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in older adults.
N Engl J Med. 2020; 383: 2427-2438
COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses.
Nature. 2020; 586: 594-599
Immunogenicity and safety of anti-SARS-CoV-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort.
Ann Rheum Dis. 2021; 0: 1-6
High antibody response to two-dose SARS-CoV-2 messenger RNA vaccination in patients with rheumatic and musculoskeletal diseases.
Ann Rheum Dis. 2021; ()
SARS-CoV-2 vaccination responses in untreated, conventionally treated and anticytokine-treated patients with immune-mediated inflammatory diseases.
Ann Rheum Dis. 2021; 0: 1-5
Antibody responses to single-dose SARS-CoV-2 vaccination in patients receiving immunomodulators for immune-mediated inflammatory disease.
Br J Dermatol. 2021; ()
Glucocorticoids and B Cell Depleting Agents Substantially Impair Immunogenicity of mRNA Vaccines to SARS-CoV-2.
medRxiv. 2021; ()
Methotrexate hampers immunogenicity to BNT162b2 mRNA COVID-19 vaccine in immune-mediated inflammatory disease.
Ann Rheum Dis. 2021; ()
A systematic review and metaanalysis of antirheumatic drugs and vaccine immunogenicity in rheumatoid arthritis.
J Rheumatol. 2018; 45: 733-744
Infliximab is associated with attenuated immunogenicity to BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines in patients with IBD.
Gut. 2021; ()
SARS-CoV-2 vaccination in immunosuppressed patients with inflammatory bowel disease: should our approach change?.
Lancet Gastroenterol Hepatol. 2021; 6: 528-529
Correspondence on immunogenicity and safety of anti-SARS-CoV-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort.
Ann Rheum Dis. 2021; ()
Rituximab, but not other antirheumatic therapies, is associated with impaired serological response to SARS- CoV-2 vaccination in patients with rheumatic diseases.
Ann Rheum Dis. 2021; ()
Humoral and cellular immune responses to SARS-CoV-2 infection and vaccination in B cell depleted autoimmune patients.
Arthritis Rheumatol. 2021; ()
SARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune response.
Ann Rheum Dis. 2021; ()
EULAR points to consider on pathophysiology and use of immunomodulatory therapies in COVID-19.
Ann Rheum Dis. 2021; 0: 21
American College of Rheumatology Guidance for the management of rheumatic disease in adult patients during the COVID-19 pandemic: version 2.
Arthritis Rheumatol. 2020; 72: e1-12
COVID-19 rapid guideline: rheumatological autoimmune, inflammatory and metabolic bone disorders.
National psoriasis foundation COVID-19 task force guidance for management of psoriatic disease during the pandemic: version 2—advances in psoriatic disease management, COVID-19 vaccines, and COVID-19 treatments.
J Am Acad Dermatol. 2021; 84: 1254-1269
Inflammatory bowel disease management during the COVID-19 outbreak: the ten do’s and don’ts from the ECCO-COVID Taskforce.
J Crohn’s Colitis. 2020; 14: S798-S806
The racial/ethnic and sociocultural aspects of the pandemic in rheumatology.
Best Pract Res Clin Rheumatol. 2021; 35101665
:strip_exif(true):strip_icc(true):no_upscale(true):quality(65)/d1vhqlrjc8h82r.cloudfront.net/08-30-2021/t_0091c848145747deab1ab60bc99ddf37_name_image.jpg)
